SUITE 310, 815 W. HASTINGS STREET, VANCOUVER, A1
Investor Webcast Script: Scheduled for 5.19.26, 8:30AM ET
Amends Preferred Investment Options
Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
InMed Pharmaceuticals Files Prospectus Supplement for Common Shares
Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Announces Positive Data from Human BrainOrganoid Neuroinflammation Models Supporting the INM-901Alzheimer's Disease Program
Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
Q3
Q2
Q1
Amended Annual Report
FY 2025
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload